Generic Name and Formulations:
Nitroglycerin 0.4% (1.5mg/inch); oint; contains lanolin.
Indications for RECTIV:
Treatment of moderate-to-severe pain associated with chronic anal fissure.
Apply using finger covering (eg, plastic-wrap, disposable surgical glove, finger cot). ≥18yrs: 1 inch of ointment intra-anally every 12 hours for up to 3 weeks. Not for oral, ophthalmic, or intravaginal use.
<18yrs: not recommended.
Concomitant PDE5 inhibitors (eg, sildenafil, vardenafil, tadalafil). Severe anemia. Increased intracranial pressure.
Volume depleted. Hypotension. Cardiomyopathy. CHF. Acute MI. Poor cardiac function. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypotension with PDE5 inhibitors, antihypertensive drugs (eg, calcium channel blockers, beta-adrenergic blockers, other nitrates). Potentiated by aspirin. Antagonizes tissue-type plasminogen activator (t-PA); caution. Anticoagulant effect of heparin may be reduced; monitor APTT. Potentiates ergotamine; possible ergotism. Additive vasodilating effects with alcohol; avoid use.
Headache, dizziness, hypotension (including orthostatic hypotension); rare: flushing, allergic reactions, application site reactions (eg, drug rash, exfoliative dermatitis), methemoglobinemia.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D